X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Aventis Enoxaparin Sodium Manufacturing Plant, Singapore

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Asia, Projects

The Jurong Island facility for the manufacture of enoxaparin sodium was opened in July 1999. Aventis commissioned the plant to meet the growing world demand for enoxaparin sodium, which had global sales in 2002 of €1.5 billion. Enoxaparin sodium was the first low-molecular-weight heparin to be introduced in the United States and Canada (approved in 1993). First approved in France in 1987, enoxaparin is now available in more than 96 countries, marketed as Lovenox (US) and Clexane (Europe).

ENOXAPARIN SODIUM IN USE

The drug is used to treat 108 million patients worldwide for deep vein thrombosis, unstable angina and non Q wave myocardial infarction. The European Society of Cardiology Congress in 2002 was presented with data, which indicated that anticoagulation therapy with enoxaparin is more effective than standard therapy using intravenous (IV) heparin and oral anticoagulants. Thus enoxaparin is becoming the accepted treatment for reducing the risk of embolism, major bleeding and death in patients undergoing cardioversion for atrial fibrillation.

PATENT CHALLENGES

Aventis announced in May 2003 that two companies were seeking to manufacture generic versions of enoxaparin sodium. The two companies, Teva Pharmaceuticals and Amphastar Pharmaceuticals, have filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration.

The two companies claim the original patent is invalid or unenforceable. They further claim the generic versions of the drug they intend to produce would not infringe the original patent, which does not expire until 14 February 2012. Aventis has filed against the two companies. Aventis is entitled to automatic stays prohibiting the FDA from approving these ANDAs for 30 months or until the courts make a ruling.

SINGAPORE AS A CENTRE FOR BIOMEDICAL EXCELLENCE

Singapore is fast becoming a regional biomedical centre. With companies such as GlaxoSmithKline, Schering-Plough, Rhone Poulenc and Merck already well established. Singapore is encouraging a burgeoning biomedical and pharmaceutical industry. The government is backing the emergence of this sector by offering attractive tax incentives and manpower training initiatives. The Tuas Biomedical park has encouraged large pharmaceutical concerns such as Pfizer, Wyeth-Ayerst and Merck to build new facilities. The Singapore government is also building the Biopolis, a world class biomedical sciences research campus, which is to open in 2003.

Local industry experts forecast that the highly lucrative Singapore market for over the counter drugs is expected to grow by 11% to 15% a year. As patients begin to rely less on doctors for minor ailments, the market for these over-the-counter drugs continues to grow. Aventis employs over 350 people in Singapore with an additional 40 people recruited as a result of the investments in both the enoxaparin sodium and the dual purpose facilities.

ENOXAPARIN SODIUM PROJECT MAKE-UP

Aventis, formed by the merger of Rhone-Poulenc Rorer and Hoechst Marion Roussel, acquired the site for the Jurong island facility in October 1995 as a result of its acquisition of Fisons Plc, a British-based pharmaceutical company. Since 1993, the site has been used for the manufacture of nedocromil sodium. The three-storey facility, which cost $50 million and was opened in 1999, has more than doubled the company’s production of enoxaparin sodium. The present facility continues to make nedocromil sodium which is used in Tilade for the treatment of asthma. Aventis has also extended the facility on an adjacent four-acre plot at a cost of $15 million to manufacture increased supplies of sodium nedocromil and also sodium cromoglycate. Sodium cromoglycate is used in Intal for the treatment of ocular and nasal allergy conditions.

Tags: Asia Pacific
Previous Post

Dainippon Sumitomo Pharma's Chemistry Research Building, Osaka, Japan

Next Post

Viropro cGMP Biomanufacturing Facility, Malaysia

Related Posts

Indian Pharmaceutical Industry In 2021 And The Road Ahead
Asia

Indian Pharmaceutical Industry In 2021 And The Road Ahead

24th January 2022
Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Asia

India crosses historic one billion COVID-19 vaccine milestone

26th October 2021
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
Asia

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

5th August 2021
Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
Asia

Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market

17th May 2021
India authorises DRDO's oxygen dependence-lowering drug for Covid-19
Asia

India authorises DRDO’s oxygen dependence-lowering drug for Covid-19

11th May 2021
New dates for MEDICAL FAIR THAILAND with move to 2022
Asia

New dates for MEDICAL FAIR THAILAND with move to 2022

30th April 2021
Next Post

Viropro cGMP Biomanufacturing Facility, Malaysia

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In